Sort
23,748 grants matching “melanoma”
Identification of Drug Targets and Their Validation in Cancer Therapy Design
$400,000Aniruddha Datta · Texas A&M Engineering Experiment Station · · FY2016 · ENG
Cancer Center Support Grant (CCSG)
$400,000George J Weiner · University Of Iowa · P30 · FY2016 · CA
A Novel Lentivector for Enhanced In Vivo Delivery of T Cell Receptors for Cell Therapy for Stage IV Melanoma
$400,000David Scott Johnson · Gigamune, Inc. · R44 · FY2025 · CA
(IND 102,133) Inhibition of Aurora Kinase A as Treatment For Melanoma
$399,999Jeffrey A Sosman · Vanderbilt University · R01 · FY2010 · FD
SPATIAL PROTEOGENOMICS TO IDENTIFY NOVEL PROGNOSTIC AND PREDICTIVE BIOMARKERS IN MELANOMA
$399,990The University Of Iowa · · FY2025 · Defense Health Agency
Modulation of cancer induced immune suppression via inhibition of SCD1
$399,986Karen E Hayes · Modulation Therapeutics, Inc. · R44 · FY2022 · CA
Development of a potent and highly brain-penetrable antimitotic agent SEAK193 to treat breast cancer brain metastasis
$399,981Wei Li · Seak Therapeutics, Llc · R41 · FY2025 · CA
A Novel Melanoma Vaccine Based on a Shared Neoantigen and a Liquid Polymer Platform
$399,979Chun Wang · Trekka Therapeutics, Llc · R41 · FY2023 · CA
Hybrid Deterministic-Stochastic Methodology for Simulating Spatial Evolution in Large Populations
$399,976Dominik Wodarz · University Of California-Irvine · · FY2018 · MPS
Understanding PPARgamma signaling in melanoma brain metastasis
$399,971Qing Chen · Wistar Institute · R01 · FY2022 · CA
Developmental Funds
$399,936Dario C. Altieri · Wistar Institute · P30 · FY2021 · CA
Developmental Funds
$399,936Dario C. Altieri · Wistar Institute · P30 · FY2023 · CA
Developmental Funds
$399,936Dario C. Altieri · Wistar Institute · P30 · FY2022 · CA
Development of a user-friendly next generation epigenomic chip adaptable to automation workflows
$399,929Timothy S McConnell · Atlasxomics Inc. · R43 · FY2024 · HG
An off-the-shelf tumor cell vaccine with HLA-matching alleles for the personalized treatment of advanced solid tumors
$399,918William Valentine Williams · Briacell Therapeutics Corp · R43 · FY2023 · CA
Bioengineering approaches to map mechanotransduction in the living cell
$399,896Ning Wang · Northeastern University · R01 · FY2024 · GM
Development and Pre-Clinical Validation of Quantitative Imaging of Cell State Kinetics (QuICK) for Functional Precision Oncology
$399,891Thomas Andrew Zangle · Utah State Higher Education System--University Of Utah · R01 · FY2025 · CA
Targeted Depalmitoylation for the Treatment of NRas-Driven Melanoma
$399,888Andrew Rudd · Palm Therapeutics, Inc. · R43 · FY2020 · CA
Targeting Fibroblast Growth Factor Receptor-2b in prevention and treatment of cutaneous Squamous cell carcinoma.
$399,821Cherie-Ann O Nathan · Louisiana State Univ Hsc Shreveport · R01 · FY2018 · CA
Human specific STING agonists for the treatment of cancer
$399,812Glen N Barber · Stinginn, Llc · R41 · FY2023 · CA
Arylsulfonamides for the Treatment of Primary and Metastatic Uveal Melanoma
$399,774Margaret Kenny Offermann · Oncospherix, Inc. · R43 · FY2020 · CA
Modulation of the gut microbiome to enhance efficacy of immunotherapy in pancreatic adenocarcinoma
$399,752Deepak Saxena · Periomics Care, Llc · R41 · FY2020 · CA
Engineering a potent locally-acting interleukin 12-expressing synthetic self-replicating mRNA to augment responses to anti-PD-1 therapy in neoadjuvant triple negative breast cancer
$399,725Tasuku Kitada · Strand Therapeutics Inc · R43 · FY2021 · CA
Development of a novel personalized medicine platform using apheretically isolated circulating tumor cells to assess drug responsiveness in prostate cancer
$399,678Jayant Parthasarathy · Astrin Biosciences, Inc. · R41 · FY2022 · CA
Engineered Glioblastoma-specific T cells using Immunostimulatory Photothermal Nanoparticles
$399,669Elizabeth E Sweeney · Immunoblue, Llc · R41 · FY2024 · CA